Shandong Sanyuan Biotechnology Co.,Ltd. (SHE:301206)
China · Delayed Price · Currency is CNY 24.93
-0.16 (-0.64%)
May 29, 2026, 3:04 PM CST
SHE:301206 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 700.46 | 625.88 | 698.51 | 482.71 | 655.82 | 1,641 |
Other Revenue | 23.63 | 23.63 | 14.4 | 16.79 | 19.09 | 33.93 |
| 724.09 | 649.51 | 712.9 | 499.5 | 674.91 | 1,675 | |
Revenue Growth (YoY) | 7.88% | -8.89% | 42.72% | -25.99% | -59.71% | 113.91% |
Cost of Revenue | 610.43 | 546.82 | 635.4 | 485.47 | 586.98 | 973.9 |
Gross Profit | 113.65 | 102.69 | 77.51 | 14.03 | 87.92 | 701.42 |
Selling, General & Admin | 37.45 | 36.15 | 25.05 | 20.05 | 20.3 | 18.8 |
Research & Development | 32.91 | 34.42 | 41.23 | 50.66 | 34.08 | 59 |
Other Operating Expenses | 3.41 | 3.44 | 2.88 | 2.54 | 3.21 | 7.01 |
Operating Expenses | 73.6 | 73.84 | 69.8 | 73.31 | 57.34 | 85.17 |
Operating Income | 40.06 | 28.86 | 7.71 | -59.28 | 30.58 | 616.26 |
Interest Expense | - | - | - | - | - | -0 |
Interest & Investment Income | 67.13 | 76.23 | 111.41 | 117.1 | 100.34 | 3.5 |
Currency Exchange Gain (Loss) | -1.39 | -1.39 | 7.45 | 2.68 | 42.83 | -7.47 |
Other Non Operating Income (Expenses) | -2.63 | -0.26 | -0.25 | -0.2 | -0.27 | -0.73 |
EBT Excluding Unusual Items | 103.16 | 103.43 | 126.31 | 60.31 | 173.48 | 611.55 |
Gain (Loss) on Sale of Investments | 2.31 | 0.37 | - | -2.89 | -0.33 | 0.26 |
Gain (Loss) on Sale of Assets | 0.06 | 0.07 | - | - | - | -0.59 |
Asset Writedown | -0.14 | - | -0.07 | - | -0.21 | -0.01 |
Other Unusual Items | 1.56 | 1.56 | 1.96 | 1.4 | 11.02 | 8.68 |
Pretax Income | 106.97 | 105.43 | 128.2 | 58.82 | 183.96 | 619.9 |
Income Tax Expense | 14.47 | 14.13 | 23.25 | 2.84 | 20.27 | 84.48 |
Earnings From Continuing Operations | 92.5 | 91.3 | 104.95 | 55.98 | 163.69 | 535.42 |
Minority Interest in Earnings | 0.09 | 0.11 | - | - | - | - |
Net Income | 92.59 | 91.41 | 104.95 | 55.98 | 163.69 | 535.42 |
Net Income to Common | 92.59 | 91.41 | 104.95 | 55.98 | 163.69 | 535.42 |
Net Income Growth | -12.34% | -12.90% | 87.47% | -65.80% | -69.43% | 130.21% |
Shares Outstanding (Basic) | 197 | 199 | 202 | 200 | 200 | 152 |
Shares Outstanding (Diluted) | 197 | 199 | 202 | 200 | 200 | 152 |
Shares Change (YoY) | -3.06% | -1.54% | 0.95% | 0.16% | 31.61% | -0.00% |
EPS (Basic) | 0.47 | 0.46 | 0.52 | 0.28 | 0.82 | 3.53 |
EPS (Diluted) | 0.47 | 0.46 | 0.52 | 0.28 | 0.82 | 3.53 |
EPS Growth | -9.56% | -11.54% | 85.71% | -65.85% | -76.77% | 130.22% |
Free Cash Flow | -152.72 | -176.33 | -155.41 | -65.68 | -158.4 | 207.7 |
Free Cash Flow Per Share | -0.78 | -0.89 | -0.77 | -0.33 | -0.79 | 1.37 |
Dividend Per Share | 1.000 | 1.000 | 1.400 | 0.250 | 0.700 | 0.667 |
Dividend Growth | -28.57% | -28.57% | 460.00% | -64.29% | 5.00% | 42.85% |
Gross Margin | 15.70% | 15.81% | 10.87% | 2.81% | 13.03% | 41.87% |
Operating Margin | 5.53% | 4.44% | 1.08% | -11.87% | 4.53% | 36.78% |
Profit Margin | 12.79% | 14.07% | 14.72% | 11.21% | 24.25% | 31.96% |
Free Cash Flow Margin | -21.09% | -27.15% | -21.80% | -13.15% | -23.47% | 12.40% |
EBITDA | 115.36 | 102.35 | 73.97 | 0.32 | 69.33 | 641.9 |
EBITDA Margin | 15.93% | 15.76% | 10.38% | 0.07% | 10.27% | 38.31% |
D&A For EBITDA | 75.3 | 73.49 | 66.26 | 59.61 | 38.75 | 25.65 |
EBIT | 40.06 | 28.86 | 7.71 | -59.28 | 30.58 | 616.26 |
EBIT Margin | 5.53% | 4.44% | 1.08% | -11.87% | 4.53% | 36.78% |
Effective Tax Rate | 13.53% | 13.40% | 18.14% | 4.82% | 11.02% | 13.63% |
Revenue as Reported | 649.51 | 649.51 | 712.9 | 499.5 | 674.91 | 1,675 |
Advertising Expenses | - | 1.16 | 1.26 | 1.17 | 0.72 | 1.08 |